Improving Outcomes for Adolescent/Young Adult and Adult Patients with ALL: Evaluating the Impact of Immunotherapy

Target Audience
The activity is intended primarily for hematology/oncology and medical oncology physicians and advanced practitioners caring for adult and AYA patients. Pediatric hematology/oncology and oncology clinicians who care for AYA patients may also find this material useful.

Program Overview
On-demand Oncology Expert Exchange: Clinical Case Challenge activity (Virtual Video Roundtable with Clinical Cases) with compelling reinforcing features. This initiative aims to close knowledge and competence gaps that result from the evolving clinical landscape to help HCPs enact appropriate treatment decision-making strategies for adult and AYA patients with ALL.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Recognize the significance of MRD monitoring in risk stratification, prognosis, and treatment selection in ALL
Review strategies to assess and interpret MRD during and after ALL treatment
Assess the clinical utility of immunotherapy agents in adult/AYA patients with MRD-positive or R/R ALL
Evaluate recent data on immunotherapy as part of chemotherapy free first-line treatment paradigms for ALL
Apply strategies to optimize treatment selections and management in adult/AYA ALL patients using clinical scenarios